Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EDAP
stocks logo

EDAP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
20.50M
-6.46%
-0.141
+162.06%
15.16M
-0.2%
-0.180
-15.43%
18.40M
-1.19%
-0.170
-2.37%
Estimates Revision
The market is revising No Change the revenue expectations for EDAP TMS S.A. (EDAP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.96%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-4.96%
In Past 3 Month
Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.395
sliders
Low
14.00
Averages
14.00
High
14.00
Current: 2.395
sliders
Low
14.00
Averages
14.00
High
14.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$19 -> $14
2025-05-16
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$19 -> $14
2025-05-16
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on EDAP TMS to $14 from $19 and keeps a Buy rating on the shares following the Q1 report. The firm accounts for management's de-emphasizing the noncore businesses.
Piper Sandler
Overweight -> Neutral
downgrade
2025-05-15
Reason
Piper Sandler
Price Target
2025-05-15
downgrade
Overweight -> Neutral
Reason
Jefferies
Michael Sarcone
Strong Buy
to
Hold
Downgrades
$8 → $2
2025-04-04
Reason
Jefferies
Michael Sarcone
Price Target
$8 → $2
2025-04-04
Downgrades
Strong Buy
to
Hold
Reason
Jefferies downgraded EDAP TMS to Hold from Buy with a price target of $2, down from $8. The firm sees downside to consensus estimates. While the company's high intensity focused ultrasound sales should growth in the mid-teens range, consensus expects higher, leaving numbers too high in the near to mid-term, the analyst tells investors in a research note. Jefferies does not incorporate sales from endometriosis or benign prostatic hyperplasia applications for EDAP TMS, citing regulatory and timeline uncertainty.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$19
2025-03-28
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$19
2025-03-28
Reiterates
Strong Buy
Reason
Piper Sandler
Jason Bednar
Buy
Maintains
$5 → $4.5
2025-03-28
Reason
Piper Sandler
Jason Bednar
Price Target
$5 → $4.5
2025-03-28
Maintains
Buy
Reason
Piper Sandler lowered the firm's price target on EDAP TMS to $4.50 from $5 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 results, including revenue of $21.5M/+1.1% year-over-year vs. Street's $21M/PSC $20.9M, confirming Piper's view that above-expected revenue was likely after learning in January the sales team locked in a record Focal One quarter. The firm continues to see EDAP as undervalued at current levels.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Edap Tms SA (EDAP.O) is -3.62, compared to its 5-year average forward P/E of -49.28. For a more detailed relative valuation and DCF analysis to assess Edap Tms SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-49.28
Current PE
-3.62
Overvalued PE
105.14
Undervalued PE
-203.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-68.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
123.80
Undervalued EV/EBITDA
-261.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.29
Current PS
0.00
Overvalued PS
4.80
Undervalued PS
1.78
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 13044.55% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EDAP News & Events

Events Timeline

(ET)
2025-11-20
07:33:12
EDAP TMS Secures FDA 510(k) Approval for Focal One Robotic HIFU
select
2025-11-06 (ET)
2025-11-06
07:48:03
EDAP TMS announces Q3 earnings per share of 16 cents, compared to a loss of 19 cents in the previous year.
select
2025-10-20 (ET)
2025-10-20
08:42:54
EDAP TMS Secures €36 Million Credit Facility from EIB
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-24Newsfilter
EDAP Receives FDA 510(k) Clearance for Enhanced Focal One HIFU System
  • FDA Clearance: EDAP TMS SA announced that its Focal One High Intensity Focused Ultrasound (HIFU) system has received FDA 510(k) clearance, further solidifying the company's market leadership in robotic focal therapy for prostate cancer. This clearance introduces advanced ultrasound imaging and an optimized user interface, enhancing treatment planning efficiency.
  • Technological Innovation: The next-generation ultrasound imaging engine provides real-time visualization and supports the development of AI-driven algorithms to assist surgeons with tissue ablation visualization and treatment evaluation. This technological advancement not only improves treatment outcomes but may also expand the indications for Focal One.
  • Market Outlook: CEO Ryan Rhodes stated that this FDA clearance represents an important technical milestone in Focal One's product roadmap, demonstrating the company's ongoing commitment to innovation. This will help the company further strengthen its leadership position in the global market, particularly in prostate cancer treatment.
  • Company Background: EDAP TMS is a recognized leader in robotic energy-based therapies, focusing on the development and distribution of minimally invasive medical devices for various conditions. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP aims to meet the growing market demand.
[object Object]
Preview
8.5
10-29NASDAQ.COM
GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

  • Genenta Science S.p.A. Update: After a significant drop in regular trading due to a $15 million capital raise announcement, Genenta's shares saw a modest recovery in after-hours trading, indicating potential stabilization as investors assess the long-term impact of the company's strategic collaborations.

  • EDAP TMS S.A. Recovery: Despite a sharp decline during the day, EDAP's stock rebounded in after-hours trading, reflecting renewed speculative interest, particularly ahead of upcoming investor meetings at the UBS Global Healthcare Conference.

  • BridgeBio Pharma Inc. Anticipation: BridgeBio's shares rose significantly after hours, driven by investor optimism regarding the upcoming Phase 3 trial results for ADH1, with topline data expected to be released soon.

  • OrthoPediatrics Corp. Financial Performance: Following the release of its Q3 financial results, OrthoPediatrics experienced a surge in after-hours trading, buoyed by revenue growth and FDA approvals, leading to an optimistic revision of its full-year revenue guidance.

[object Object]
Preview
9.0
10-17Newsfilter
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market

  • Advancements in Cancer Immunotherapy: MIT and Harvard scientists have engineered CAR-NK cells that evade the immune system, enhancing cancer destruction and enabling immediate off-the-shelf treatments. The global cancer immunotherapy market is projected to grow significantly, driven by innovations in cellular therapies and biomarker-driven drug development.

  • GT Biopharma's Clinical Progress: GT Biopharma is advancing its Phase 1 trial of GTB-3650 for treating relapsed or refractory blood cancers, showing promising early results in immune activation without significant side effects. The company plans to file for human trials of its solid tumor-targeting therapy, GTB-5550, by late 2025.

  • Evaxion's Personalized Cancer Vaccine: Evaxion A/S is set to present two-year data from its Phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine, demonstrating a 69% overall response rate in advanced melanoma patients. The company emphasizes the importance of personalized therapies in oncology.

  • RenovoRx and EDAP TMS Innovations: RenovoRx has initiated a registry study to evaluate its drug-delivery device, RenovoCath, for solid tumors, while EDAP TMS gained national attention for its non-invasive Focal One Robotic HIFU treatment for prostate cancer, highlighting advancements in minimally invasive cancer therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Edap Tms SA (EDAP) stock price today?

The current price of EDAP is 2.395 USD — it has decreased -0.62 % in the last trading day.

arrow icon

What is Edap Tms SA (EDAP)'s business?

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

arrow icon

What is the price predicton of EDAP Stock?

Wall Street analysts forecast EDAP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDAP is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Edap Tms SA (EDAP)'s revenue for the last quarter?

Edap Tms SA revenue for the last quarter amounts to 13.88M USD, increased 5.96 % YoY.

arrow icon

What is Edap Tms SA (EDAP)'s earnings per share (EPS) for the last quarter?

Edap Tms SA. EPS for the last quarter amounts to -0.13 USD, decreased -23.53 % YoY.

arrow icon

What changes have occurred in the market's expectations for Edap Tms SA (EDAP)'s fundamentals?

The market is revising No Change the revenue expectations for EDAP TMS S.A. (EDAP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -4.96%.
arrow icon

How many employees does Edap Tms SA (EDAP). have?

Edap Tms SA (EDAP) has 310 emplpoyees as of December 05 2025.

arrow icon

What is Edap Tms SA (EDAP) market cap?

Today EDAP has the market capitalization of 89.55M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free